ANTEOTECH LTD — Capital/Financing Update 2016

Sep 8, 2016

==> picture [315 x 91] intentionally omitted <==

R&D Tax Incentive Received

9 September, 2016: Anteo Diagnostics Limited (ASX: ADO) advises that it has received a $2,061,301 cash refund under the Federal Government’s R&D Tax Incentive Scheme.

The refund relates to the costs of research and development which qualify as eligible R&D expenditure under the Federal Government’s Scheme. The funds will be used to advance Anteo’s nanochemistry coating programs.

The Australian R&D Tax Incentive is an important factor contributing to the success of Anteo’s development program. The cash refund enables Anteo to undertake more R&D than would otherwise be possible.

About Anteo Diagnostics Limited

Anteo Diagnostics Limited (ASX: ADO) is a global nanochemistry technology company, developing and commercializing products for the life sciences and clinical diagnostics, medical devices, and energy, and bioseparations markets. The Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent bindings with the gentleness of passive bindings through multi-point chelation. Used as a binder, coating or primer, Anteo’s reagents target high-value commercial applications in protein binding and anti-body coupling (e.g point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings in batteries, and this across a broad range of industry sectors.

Media contact – Lyndsey Douglas 0424203935

==> picture [596 x 138] intentionally omitted <==